The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InMoonLake Immunotherapeutics has released long-term Week 40 data from its global Phase 3 registrational program for Sonelokimab. The results stem from the VELA-1 and VELA-2 trials, focusing on patients with moderate-to-severe Hidradenitis Suppurativa (HS). This clinical data was presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting. The long-term data is a critical component of the registrational program intended to support upcoming regulatory filings for drug approval. Analysts view the positive outcome as a significant de-risking event for the clinical-stage biotech company as it moves toward potential commercialization. These results are essential for seeking future approval from major regulatory bodies including the FDA and EMA. The announcement reinforces MoonLake's position in the competitive landscape of inflammatory skin disease treatments.